# **Document Update Notification**

COPYHOLDER NO: 103

ĩ,

TO:	NRC - WASHINGTON
ADDRESS:	OS-DOC CNTRL DESK MAIL STOP OP1- 17 WASHINGTON DC 20555-DC
DOCUMENT NO:	OP-1903.035
TITLE:	ADMINISTRATION OF POTASSIUM IODIDE
REVISION NO:	007-00-0
CHANGE NO:	AP-07
SUBJECT:	NEW REVISION

 $\mathbf{H} \leftarrow \mathbf{I} \mathbf{f}$  this box is checked, please sign, date, and return within 5 days.



ANO-1 Docket 50-313

ANO-2 Docket 50-368

Signature

Date

ADOI

SIGNATURE CONFIRMS UPDATE HAS BEEN MADE

**RETURN TO:** 

ATTN: DOCUMENT CONTROL ARKANSAS NUCLEAR ONE 1448 SR 333 RUSSELLVILLE, AR 72801

ENTERGY OPERATIONS IN ARKANSAS NUCLE	ICORPORATED AR ONE					
TITLE: ADMINISTRATION OF POTASSIUM IODIDE	DOCUMENT NO. 1903.035 WORK PLAN EXP. DATE	CHANGE NO. 007-00-0 TC EXP. DATE N/A				
set # 103	N/A SAFETY-RELATED ⊠YES □NO TEMP ALT □YES ⊠NO					
TRAPS	Get these TOOL	S				
When you see these <u>TRAPS</u> Time Pressure		ommunication				
Distraction/Interruption	Questioning	g Attitude				
Multiple Tasks	Placekeepir	ng				
Overconfidence	Self Check					
Vague or Interpretive Guidance	Peer Check					
First Shift/Last Shift	Knowledge					
Peer Pressure	Procedures					
Change/Off Normal	Job Briefing					
Physical Environment	Coaching					
Mental Stress (Home or Work)	Turnover					
VERIFIED BY DATE	TIME					
VERIFIED OF						
FORM TITLE: VERIFICATION COVER SHEET	FORM 1000	NO. CHANGE NO. .006A 050-00-0				

ż

1

ENTERGY OPERA ARKANSA	ATIONS INCORP AS NUCLEAR ON	ORATED E		
TITLE: ADMINISTRATION OF POTASSIUM IODIDE			IENT NO. 3.035	Page CHANGE NO. 007-00-0
	ELECTRONIC DO	CUMENT	SAFETY-R	ÉLATED
TYPE OF CHANGE:         □ NEW       □ PC         ☑ REVISION       □ EZ	TC EXF	. DATE: <u>N/A</u>		
DOES THIS DOCUMENT: 1. Supersede or replace another procedure?				⊠ NO
<ul><li>(If YES, complete 1000.006B for deleted procedure.) (0C/</li><li>2. Alter or delete an existing regulatory commitment?</li></ul>	-			NO NO
(If YES, coordinate with Licensing before implementing.) ( 3. Require a 50.59 review per LI-101? (See also 1000.006, A	••	049803)	YES	
<ul> <li>(If 50.59 evaluation, OSRC review required.)</li> <li>4. Cause the MTCL to be untrue? (See Step 8.5 for details.) (If YES, complete 1000.009A) (1CAN108904, 0CAN09900</li> </ul>		AND49803)	VES	NO NO
<ol> <li>Create an Intent Change? (If YES, Standard Approval Process required.)</li> </ol>	n, cona 2000, co		T YES	NO NO
6. Implement or change IPTE requirements? (If YES, complete 1000.143A. OSRC review required.)			YES	NO NO
<ol> <li>Implement or change a Temporary Alteration? (If YES, then OSRC review required.)</li> </ol>			YES	NO NO
Was the Master Electronic File used as the source document?			YES	
INTERIM APPROVAL PROCESS			ROVAL PROCE	
ORIGINATOR SIGNATURE: (Includes review of Att. 13) DATE:		TURE: (Includes)	review of Att. 13) D	ATE: 10/8/01
Print and Sign name: PHONE #: SUPERVISOR APPROVAL: * DATE:	Print and Sign name: R		a	HONE #: 4993
SRO UNIT ONE :** DATE:	ENGINEERING:			0/9/01 ATE:
SRO UNIT TWO: ** DATE:	QUALITY:	<u>N/A</u>	D	ATE:
Interim approval allowed for non-intent changes requiring no 50.59 evaluation that are stopping work in progress.	UNIT SURVEILLANCE		(OCNA049803): D	ATE:
Standard Approval required for intent changes or changes requiring a 50.59 evaluation.	SECTION LEADER:	De_	10	ate: -18-01
*If change not required to support work in progress, Department Head must sign. **If both units are affected by change, both SRO signatures	QUALITY ASSURANC	E: NA		
are required. (SRO signature required for safety related procedures only.)	OTHER SECTION LE	DERS:		16/01 ATE:
	OTHER SECTION LE	DERS	G	15/01 ATE;
	OTHER SECTION LEA	DERS:		18/01
OSRO CHAIRMAN/TECHNICAL REVIEWER: (OCNA049312) DATE:	OTHER SECTION LEA			ATE:
FINAL APPROVAL: Date: 10-19-201	OTHER SECTION LEA			
REQUIRED EFFECTIVE DATE: 10/23/01 FORM TITLE:	OTHER SECTION LEA	T	FORM NO.	ATE:
PROCEDURE/WORK PLAN APPRO			1000.006B	CHANGE NO. 051-00-0

ENTERGY OPERATIONS INCORPORATED ARKANSAS NUCLEAR ONE							
TITLE: ADMINISTRAT	TON OF POTASSIUM IODIDE DOCUMENT NO. 1903.035	CHANGE N 007	o. <b>'-00-0</b>				
	WORK PLAN, EXP. DATE N/A	PAGE _1	OF_1				
	MENT						
TYPE OF CHANGE:	$\Box = EZ \qquad EXP. DATE: N/A$						
AFFECTED SECTION: (Include step # if applicable)	DESCRIPTION OF CHANGE: (For each change made, include reason for the change.)		) describe				
5.1	Added "(or the Shift Manager if the RP&RW Manager is not ava	ilable)".					
5.3	Added "(or Shift Manage if the TSC Director is not available)".						
6.1 NOTE	Re-worded note for clarity and moved note above 6.1.1.		14 OF D				
6.1.2	Added step to allow for procedure to be used when it is not possible to determine if 25 Rem CDE will be exceeded.						
6.2.1	Re-worded to indicate the method used for determination of net						
6.2.1.A	Added step for using Attachment 1 to determine need to issue I						
6.21.B	Added step for using other parameters to determine need to iss						
6.2.2	Changed step so that the reason for issuing KI is indicated on a	1903.035A.	_				
6.2.3	Added Shift Manager to list of personnel to report results of KI		to.				
6.2.4	Added Shift Manager to list of personnel who may authorize is	sue of KI.					
6.3.1	Deleted step. Information is in a previous step.						
6.3.2	Re-numbered to 6.3.1 and added Shift Manager to list of person receive and who shall issue KI.	onnel to designat	e wno snali				
6.3.3	Re-numbered to 6.3.2.						
6.3.4	Re-numbered to 6.3.3.						
6.4 NOTE	NOTE Added Control Room to list of storage locations for KI.						
6.5	Added Shift Manager to list of personnel who may authorize is	sue of KI.	4				
1903.035A	Added "Unknown, large exposure possible" to Estimated Thyr Added Shift Manager to approval signature line.						
1903.035C	Deleted question about "known allergies". Question is not ne indicated by the other questions.	FORM NO.	CHANGE NO.				
FORM TITLE:	DESCRIPTION OF CHANGE	1000.006C	050-00-0				

1,

3

Ċ,

٠

# TABLE OF CONTENTS

## PAGE NO.

SECTIC	<u>N</u>		2
1.0	Purpose		2
2.0	Scope		
3.0	Referen	ces	2
4.0			2
5.0			Authority2
6.0	Instruc		
	6.1		g Conditions3
	6.2		the Need to Issue KI3
	6.3	KI Issuand	ce Requirements3
	6.4	Distribut	ion of KI4
	6.5	Guideline	s for the Administration of KI5
	6.6	Final Con	ditions6
7.0	Attach	ments and Fo	orms
	7.1	Attachmen	ts
		7.1.1	Attachment 1 - Thyroid Committed Dose Equiv. Graph7
		7.1.2	Attachment 2 - Potassium Iodide Precaution Leaflet9
	7.2	Forms	
		7.2.1	Form 1903.035A - Potassium Iodide Administration10
		7.2.2	Form 1903.035B - KI Issue Record
		7.2.3	Form 1903.035C - ANO Medical Questionnaire Todine Sensitivity12

#### 1.0 PURPOSE

To provide guidance for the administration of Potassium Iodide (KI) to minimize uptake of radioiodines in the thyroid gland.

2.0 SCOPE

This procedure applies to all ANO and contractor employees prior to a planned exposure to radioiodine and after an accidental exposure.

#### 3.0 REFERENCES

- 3.1 REFERENCES USED IN PROCEDURE PREPARATION:
  - 3.1.1 EPA 400-R-92-001, Manual of Protective Action Guides and Protective Actions for Nuclear Incidents
  - 3.1.2 Patient Package Insert for Commercially Packaged Potassium Iodide
  - 3.1.3 ANO Emergency Plan
- 3.2 REFERENCES USED IN CONJUNCTION WITH THIS PROCEDURE:
  - 3.2.1 1903.033, "Protective Action Guidelines for Rescue/Repair and Damage Control Teams"
  - 3.2.2 1903.065, "Emergency Response Facility Technical Support Center (TSC)
  - 3.2.3 1903.067, "Emergency Response Facility Emergency Operations Facility (EOF)
- 3.3 RELATED ANO PROCEDURES:

1903.060, "Emergency Supplies and Equipment"

3.4 REGULATORY CORRESPONDENCE CONTAINING NRC COMMITMENTS WHICH ARE IMPLEMENTED IN THIS PROCEDURE: Commitments noted in [BOLD]

3.4.1 Letter 0CNA049709 Inspection report 97-10, 6.4 NOTE

4.0 DEFINITIONS

None

## 5.0 RESPONSIBILITY AND AUTHORITY

- 5.1 The Radiation Protection and Radwaste (RP&RW) Manager (or the Shift Manager if the RP&RW Manager is not available) is responsible for the implementation of this procedure for on-site emergency response personnel.
- 5.2 The Radiological Environmental Assessment Manager (REAM) is responsible for the implementation of this procedure for off-site emergency response personnel.

- 5.3 The TSC Director (or Shift Manager if the TSC Director is not available) is responsible for authorizing the administration of KI for on-site emergency response personnel.
- 5.4 The EOF Director is responsible for authorizing the administration of KI for offsite emergency response personnel.

### 6.0 INSTRUCTIONS

6.1 INITIATING CONDITIONS

**NOTE** Parameters other than air sample results (for example, RDACS, failed fuel monitor, etc.) that indicate the presence (or potential presence) of significant amounts of radioactive iodine may be used when making the decision to administer KI.

- 6.1.1 This procedure shall be initiated whenever a dose commitment of 25 Rem CDE or greater for the thyroid is likely to be received by an individual.
- 6.1.2 This procedure shall be initiated whenever exposure to large amounts of radioactive airborne iodine is possible and it is not possible to determine if 25 Rem CDE will be exceeded.
- 6.2 ASSESSING THE NEED TO ISSUE KI
  - 6.2.1 Determine the need to issue KI by either of the following methods:
    - A. Using Attachment 1, "Thyroid Committed Dose Equivalent Graph", estimate the dose commitment for the thyroid.
    - B. Using other parameters (RDACS, failed fuel monitor, etc.), determine if exposure to significant levels of radioactive iodine is possible.
  - 6.2.2 Indicate the reason for issuing KI on Form 1903.035A, Potassium Iodide Administration Form.
  - 6.2.3 Report the results to the Shift Manager, TSC Director, or EOF Director and advise him or her of the need to issue KI.
  - 6.2.4 The Shift Manager, TSC Director, or EOF Director may approve the issuance of KI via telecom.
- 6.3 KI ISSUANCE REQUIREMENTS
  - 6.3.1 The Shift Manager, TSC Director, or EOF Director shall designate the individuals who will receive KI and the individuals to administer KI.
  - 6.3.2 The individual(s) to receive KI shall voluntarily elect to take KI.

6.3.3 The individual(s) to receive KI shall read Attachment 2, Potassium Iodide Precaution Leaflet, and complete the appropriate sections of Form 1903.035A, "Potassium Iodide Administration Form", and Form 1903.035C, "ANO Medical Questionnaire: Iodine Sensitivity".

 INOTE

 KI is stored in the following locations:

 A. TSC Emergency Kit

 B. Onsite Radiological Monitoring Kit (located in the OSC)

 C. EOF Emergency Kit

 D. Field Monitoring Kits (located in the EOF)

 E. Control Room Emergency Kit]

 6.4.1
 Assemble the individuals who were designated to receive KI and the individuals to administer the KI.


- 6.4.2 Provide the individuals designated to receive KI with copies of:
  - A. Form 1903.035A, "Potassium Iodide Administration Form"
  - B. Attachment 2, "Potassium Iodide Precaution Leaflet"
  - C. Form 1903.035C, "ANO Medical Questionnaire: Iodine Sensitivity"
- 6.4.3 The individuals designated to administer KI should obtain copies of Form 1903.035B, "KI Issue Record".
- 6.4.4 Ensure personnel read and/or complete the appropriate sections of the Forms and Attachments provided in Step 6.4.2.

<sup>6.4</sup> DISTRIBUTION OF KI

PROC./WORK PLAN NO. 1903.035	PROCEDU	RE/WORK PLAN TITLE: ADMINISTRATION OF POTASSIUM IODIDE	PAGE: CHANGE:	5 of 12 007-00-0
6.5		ES FOR THE ADMINISTRATION OF KI		
	administ	t Manager, TSC Director, or EOF Director can ration of KI in the field after the Field Mo have complied with the guidelines of this p btained via telecom.	rocedure.	Approval
	6.5.1	If possible, KI should be administered ap half hour before exposure for maximum blo	proximate ockage.	ely one-
	6.5.2	Final uptake is halved if KI is administe hours after exposure.	ered with:	in 3-4
	6.5.3	Little benefit is gained with KI administ after exposure.	tration 1	0-12 hours
	6.5.4	Once the KI is taken and the Iodine conce verified or the calculated dose determine should be issued for a minimum of six (6 ten (10) consecutive days. One tablet i	) to a ma	ximum of
	,	interne contaminatio	n is anti	cipated.

- 6.5.5 In all cases where airborne contamination is anticipated, the use of proper respiratory equipment shall be considered.
- 6.5.6 Verify that each individual receiving KI has completed and signed Forms 1903.035A and 1903.035C.
- 6.5.7 Verify that there are no "YES" blocks checked on Form 1903.035C, "ANO Medical Questionnaire: Iodine Sensitivity".
- 6.5.8 Individuals who have answered "YES" to any question on 1903.035C, "ANO Medical Questionnaire: Iodine Sensitivity", will initially be considered to be iodine sensitive and must be treated as follows:
  - A. The individuals will be relocated or replaced to eliminate or minimize the uptake of radioiodine in the thyroid gland, or
  - B. The individuals <u>WILL NOT</u> receive KI without the RP&RW Manager's/REAM's authorization (after evaluation of the "YES" answer and the TSC Director's/EOF Director's concurrence).
- 6.5.9 Issue each individual designated to receive KI one (1) 130mg KI tablet.
- 6.5.10 Record the issuance on Form 1903.035B, "KI Issue Record".
- 6.5.11 Forward all completed paperwork to the RP&RW Manager/REAM.
- 6.5.12 Individuals listed on Form 1903.035B, "KI Issue Record", should have a whole body count and/or bioassay analysis at the earliest opportunity.

1	PROC./WORK PLAN NO.	PROCEDU	RE/WORK PLAN TITLE:	PAGE:	6 of 12				
-	PROC./WORK PLAN NO. 1903.035	PROCEDO	ADMINISTRATION OF POTASSIUM IODIDE CHANGE: 007-00-0						
		6.5.13	Where possible, whole body counts and/or should be given on a regular basis throug period to verify the effectiveness of the estimate dose commitment.	nout the	TEL TOPAG				
	6.6	FINAL CON	DITIONS						
		6.6.1	Each individual whose estimated exposure equal to or exceeded 25 Rem has been iden administered KI, as appropriate.	to radio: tified an	odine was nd				
		6.6.2	All necessary forms are completed and rev Manager/REAM and the TSC Director/EOF Dir	viewed by rector.	the RP&RW				
		6.6.3	Completed documentation collected and ass RP&RW Manager and/or REAM for post-event records.	sembled b assessme	y the nts and				
		6.6.4	Each individual who was exposed to radioa been scheduled for bioassay analysis.	active io	dine has				
	7.0 <u>AT</u>	TACHMENT	S AND FORMS						
	7.1	ATTACHME	NTS						
		7.1.1	Attachment 1 - Thyroid Committed Dose Equ	uivalent	Graph				
		7.1.2	Attachment 2 - Potassium Iodide Precautio	on Leafle	t				
$\searrow$	7.2	FORMS							
		7.2.1	Form 1903.035A - Potassium Iodide Admini	stration					
		7.2.2	Form 1903.035B - KI Issue Record						
		7.2.3	Form 1903.035C - ANO Medical Questionnai Sensitivity	re: Iodir	le				




ATTACHMENT 1

THYROID COMMITTED DOSE EQUIVALENT GRAPH

Page 1 of 2

# THYROID COMMITTED DOSE EQUIVALENT GRAPH



V.			<u> </u>	
-			PAGE:	8 of 12
PROC./WORK PLAN NO.				
1903.035		POTASSIUM IODIDE ADMINISTRATION	CHANGE:	007-00-0
	_			

#### ATTACHMENT 1

# THYROID COMMITTED DOSE EQUIVALENT GRAPH

Page 2 of 2

# Instructions for Use:

- Determine the estimated or actual I-131 airborne concentration in the area(s) of interest. Divide this by the protection factor of the equipment used (if unknown, use 1). Locate this number on the horizontal axis.
- 2. Locate the duration of exposure in minutes on the vertical axis. Find the point at which this value intersects with the number form step 1.
- 3. If the point of intersection is located below the line, then the thyroid CDE is less than 25 Rem.
- 4. If the point of intersection is located on or above the line, then the thyroid CDE is equal to or greater than 25 Rem.

### ATTACHMENT 2

# POTASSIUM IODIDE PRECAUTION LEAFLET

# THYROID BLOCKING AGENT INSTRUCTION SHEET

THYRO-BLOCK TABLETS (POTASSIUM IODIDE TABLETS, USP)

(pronounced pos-TASS-e-um EYE-oh-dyed) (abbreviated: Kl)

TAKE POTASSIUM IODIDE ONLY WHEN AUTHORIZED. IN A RADIATION EMERGENCY, RADIOACTIVE IODINE COULD BE RELEASED INTO THE AIR POTASSIUM IODIDE (A FORM OF IODINE) CAN HELP PROTECT YOU.

IF YOU ARE TOLD TO TAKE THIS MEDICINE, TAKE IT ONE TIME EVERY 24 HOURS. DO NOT TAKE IT. MORE OFTEN. MORE WILL NOT HELP YOU AND MAY INCREASE THE RISK OF SIDE EFFECTS. DO NOT TAKE THIS DRUG IF YOU KNOW YOU ARE ALLERGIC TO IODIDE. (SEE SIDE EFFECTS BELOW.)

#### INDICATIONS THYROID BLOCKING IN A RADIATION EMERGENCY ONLY

#### DIRECTIONS FOR USE

Use only as directed in the event of a radiation emergency.

DOSE

Tablets: One (1) tablet once a day.

Take for 10 days unless directed otherwise by the Emergency Director or Offsite Emergency Coordinator.

Store at controlled room temperature between 15° and 30°C (59° to 86° F). Keep container tightly closed and protect from light.

#### WARNING

Potassium iodide should not be used by people allergic to iodide. Keep out of the reach of children. In case of overdose or allergic reaction, contact a physician.

#### DESCRIPTION

Each THYRO-BLOCK TABLET contains 130 mg of potassium iodide. Other ingredients: magnesium stearate, microcrystalline cellulose, silica gel, sodium thiosulfate.

### HOW POTASSIUM IODIDE WORKS

Certain forms of iodine help your thyroid gland work right. Most people get the iodine they need from foods like iodized salt or fish. The thyroid can "store" or hold only a certain amount of iodine.

In a radiation emergency, radioactive iodine may be released in the air. This material may be breathed or swallowed. It may enter the thyroid gland and damage it. The damage would probably not show itself for years.

If you take potassium iodide, it will fill up your thyroid gland. This reduces the chance that harmful radioactive iodine will enter the thyroid gland.

## WHO SHOULD NOT TAKE POTASSIUM IODIDE

The only people who should not take potassium iodide are people who know they are allergic to iodide. You may take potassium iodide even if you are taking medicines for a thyroid problem (for example, a thyroid hormone or antithyroid drug). Pregnant and nursing women may also take this drug.

# HOW AND WHEN TO TAKE POTASSIUM IODIDE

Potassium lodide should be taken as soon as possible after authorization. You should take one dose every 24 hours. More will not help you because the thyroid can "hold" only limited amounts of iodine. Larger doses will increase the risk of side effects. You will probably be told not to take the drug for more than ten days.

#### SIDE EFFECTS

Usually, side effects of potassium iodide happen when people take higher doses for a long time. You should be careful not to take more than the recommended dose or take it for longer than you are told. Side effects are unlikely because of the low dose and the short time you will be taking the drug.

Possible side effects include skin rashes, swelling of the salivary glands, and "iodism" (metallic taste, burning mouth and throat, sore teeth and gums, symptoms of a head cold, and sometimes stomach upset and diarrhea).

A few people have an allergic reaction with more serious symptoms. These could be fever and joint pains, or swelling of parts of the face and body and at times severe shortness of breath requiring immediate medical attention.

Taking iodide may rarely cause overactivity of the thyroid gland, underactivity of the thyroid gland, or enlargement of the thyroid gland (goiter).

## WHAT TO DO IF SIDE EFFECTS OCCUR

If the side effects are severe or if you have an altergic reaction, stop taking potassium lodide. Then, if possible, call a doctor or public health authority for instructions.

#### HOW SUPPLIED

THYRO-BLOCK TABLETS (Potassium lodide Tablets. USP) bottles of 14 tablets (NDC 0037-0472-20). Each while, round, scored tablet contains 130 mg potassium iodide. Potassium Iodide (KI) Administration Form

v

ŝ

Name of Exposed Individual:	Last F	irst Middle
Social Security Number:		er:
Duration of Exposure: Minutes	I-131 Conce	entration: µCi/cc in air
Estimated Thyroid Dose Commitmen		Rem □ ≥ 25 Rem wn, large exposure possible
Date of Exposure:		🗌 Yes 🗍 No
Respiratory Protection Worn Duri	ng Exposure:	L'Yes L'NO
Respirator Protection Factor:		
Known Iodide Allergy/Previous Al	lergic Reaction to iodi	.de: 🗌 Yes 🗌 No
	CAUTION s checked yes, then do r	
I verify that I have read and un that taking thyroid blocking age I Choose D do not cho	nderstand the predation ent (KI) is strictly vol	Luntary.
Signature of Exposed Indi	vidual	Date
Approved: Shift Manager/EOF Direct	tor/TSC Director via telecom.	Date
KI Issued By:Signatu	re	Date
Notes:		

	CHANGE:.	REV.
	1903.035A	007-00-0
POTASSIUM IODIDE ADMINISTRATION		

<'

## KI ISSUE RECORD

	KI ADMINISTRATION										
Person Receiving KI		Init. Dose	Dose 2	Dose 3	Dose 4	Dose 5	Dose 6	Dose 7	Dose 8	Dose 9	Dose 10
Name:	Date										
SS No:	Init.							 			
Name:	Date										
SS No:	Init.							<u> </u>			<u> </u>
Name:	Date						-				ļ
SS No:	Init.										
Name:	Date										
SS No:	Init.										
Name:	Date										
SS No:	Init.										

# Instruction for Use:

- Print the name and social security number of the individual(s) to whom KI is being administered in the blocks of the left-hand side of the form.
- The individual assigned to administer KI will date and initial the blocks under the column corresponding to the day of issuance (for example: use column 1 for the initial issue: column 2 on the second day: etc.)
- 3. Forward completed attachment to the RP&RW Manager or REAM.

	CHANGE:	REV.
FORM TITLE:	1903.035B	007-00-0
KI ISSUE RECORD	l	

Page 12 of 12

# MEDICAL QUESTIONAIRE: IODINE SENSITIVITY

رژ

5

			SS No:					
Name:	LAST F	IRST MIDDLE						
		Company:		Dept:				
Please answer the following questions. Mark the appropriate box.								
NO.		QUESTION						
1.	When eating seafood or symptoms of stomach or If so, explain below.	shellfish, do you bowel upset or sk:	suffer from in eruption?	🗌 Yes	□ No			
2.	Has any physician told to iodine?			🗌 Yes	🗌 No			
3.	Have you ever had a ga ray requiring dye inje scan?	llbladder dye test ction or a thyroid	, kidney x- isotope	🗌 Yes	🗌 No			
	If so, any reactions?			🗌 Yes	🗌 No			
Please explain any yes answers:								
<u> </u>								
Sign	ature:		Date:					

		CHANGE:	REV.
FORM		1903.035C	007-00-0
	ANO MEDICAL QUESTIONNAIRE-IODINE SENSITIVITY		